ZXZhang Xiangsong

Zhang Xiangsong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhang Xiangsong has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De Novo Glutamine Synthesis

    by Qiao He, Xinchong Shi, Linqi Zhang, Chang Yi, Xuezhen Zhang, Xiangsong Zhang

    Purpose: The aim of this study was to investigate the role of de novo glutamine (Gln) synthesis in the proliferation of C6 glioma cells and its detection with 13N-ammonia. Methods: Chronic Gln-deprived C6 glioma (0.06C6) cells were established. The proliferation rates of C6 and 0.06C6 cells were measured under the conditions of Gln deprivation along with or without the addition of ammonia or glutamine synthetase (GS) inhibitor. 13N-ammonia uptake was assessed in C6 cells by gamma counting and in rats with C6 and 0.06C6 xenografts by micro–positron emission tomography (PET) scanning. The expression of GS in C6 cells and xenografts was assessed by Western blotting and immunohistochemistry, respectively. Results: The Gln-deprived C6 cells showed decreased proliferation ability but had a significant increase in GS expression. Furthermore, we found that low concentration of ammonia was sufficient to maintain the proliferation of Gln-deprived C6 cells, and 13N-ammonia uptake in C6 cells showed Gln-dependent decrease, whereas inhibition of GS markedly reduced the proliferation of C6 cells as well as the uptake of 13N-ammoina. Additionally, microPET/computed tomography exhibited that subcutaneous 0.06C6 xenografts had higher 13N-ammonia uptake and GS expression in contrast to C6 xenografts. Conclusion: De novo Gln synthesis through ammonia–glutamate reaction plays an important role in the proliferation of C6 cells. 13N-ammonia can be a potential metabolic PET tracer for Gln-dependent tumors.


  • Usefulness of 13N-NH3 PET in the evaluation of brain lesions that are hypometabolic on 18F-FDG PET

    by Zhang Xiangsong, Chen Weian, Yue Dianchao, Wang Xiaoyan, Chen Zhifeng, Shi Xiongchong

    We investigated the usefulness of 13N-NH3 PET in characterizing brain lesions which show hypometabolism on 18F-FDG PET. 13N-NH3 PET was performed in 18 patients with brain lesions (in 14 for initial diagnosis and in 4 for detection of astrocytoma recurrence) that showed hypometabolism compared with normal brain tissue on 18F-FDG PET. The diagnoses were ten gliomas, one metastatic tumor, one dysembryoplastic neuroepithelial tumor (DNT), and six non-neoplastic lesions (including three cases of radiation necrosis, two cases of encephalitic foci, and one ischemic lesion). Diagnosis was verified by histopathological examination in 13 patients or was established by clinical follow-up and additional investigations in the remainder. Seven of 12 brain tumors (58%, sensitivity) showed increased 13N-NH3 uptake despite hypometabolism on 18F-FDG PET. The three low-grade gliomas, one metastatic tumor, and one DNT showed decreased 13N-NH3 uptake. The mean (±SD) uptake ratio of 13N-NH3 was significantly higher than that of 18F-FDG (1.24 ± 0.57 vs. 0.67 ± 0.21, P < 0.01) in the tumors. By contrast, all six non-neoplastic lesions showed decreased 13N-NH3 uptake (100% specificity). The mean (±SD) uptake ratio of 18F-FDG and 13N-NH3 in the non-neoplastic lesions was 0.68 ± 0.15 and 0.70 ± 0.19, respectively, and there was no significant difference between them (P > 0.05). The mean (±SD) uptake ratio of 13N-NH3 in the tumors was significantly higher than that in the non-neoplastic lesions (1.24 ± 0.53 vs. 0.70 ± 0.19, P < 0.05). The preliminary results of this study suggest that 13N-NH3 PET may be helpful to detect and differentiate brain tumors which show hypometabolism on 18F-FDG PET from non-neoplastic lesions with high specificity, especially for cerebral astrocytomas, but the sensitivity is relatively limited.


  • 13N-NH3: a selective contrast-enhancing tracer for brain tumor

    by Zhang Xiangsong, Wu Xinjian, Zhang Yong, Chen Weian

    The purpose of this study is to determine whether there is a qualitative and quantitative relationship between the breakdown of the blood-brain barrier, defined radiologically by the contrast enhancement of MRI, and the uptake of N-NH3 in brain tumors. The results of N-NH3 PET in 42 patients suspected of having brain tumors were compared with the findings of contrast-enhanced MRI. A histopathological diagnosis was carried out in 33 patients, and a clinical diagnosis was performed in the remaining patients. PET and MRI images were visually inspected, and the contrast index (CI) of MRI and the uptake index (UI) of N-NH3 were measured. Contrast enhancement of MRIs was seen in 20 of 29 brain tumors (69%). Increased uptake of N-NH3 was seen in 24 of 29 brain tumors (83%). Nineteen of 20 contrast-enhancing brain tumors exhibited the increased uptake of N-NH3 (95%). Areas of the increased N-NH3 uptake corresponded to areas enhanced on MR images in the majority of cases. Five out of nine nonenhancing tumors exhibited increased uptake of N-NH3 (56%). The contrast enhancement of MRIs was seen in nine of 13 nonneoplastic lesions (69%). None of the nonneoplastic lesions showed increased uptake of N-NH3, yielding a specificity of 100% for brain tumors (0 of 13). CI for tumor tissue was 1.46+/-0.64. UI of N-NH3 for tumor tissue was 1.64+/-0.71. CI and UI for tumor tissue were significantly correlated (r=0.86, P<0.01). A statistically significant difference in uptake levels of N-NH3 between contrast-enhancing tumors and nonenhancing tumors (1.88+/-0.66, n=20 vs. 1.11+/-0.52, n=9, P<0.01) was observed. UI was higher in brain tumors compared with the nonneoplastic lesions (1.64+/-0.71 vs. 0.71+/-0.19, P<0.01). N-NH3 is a potential selective contrast-enhanced tracer for brain tumor, and may prove especially useful for evaluating the contrast-enhancing lesions on MRI to distinguish brain tumors from nonneoplastic lesions.


  • Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET

    by Zhang Xiangsong, Chen Weian

    Differentiation of posttherapy radiation necrosis from recurrent brain tumor remains a challenging diagnostic problem. The combination of the imaging modalities on the basis of different physiologic mechanisms could improve diagnostic accuracy. The present study assessed the role of 13N-NH3 PET in differentiating recurrent cerebral astrocytoma from radiation necrosis. Seven patients, who were previously treated with conventional external-beam radiation therapy after surgical resection for cerebral astrocytomas, and showed the enhancing brain lesions on T1-weighted gadiolinium-enhanced MR studies performed in 6 months or above after the radiotherapies, were examined prospectively with 13N-NH3 and FDG PET. Five lesions with tumor recurrence and two with radiation necrosis were histologically verified by either surgical resection or stereotactic biopsy. One lesion of radiation necrosis was confirmed clinicoradiologically. In all eight lesions the 13N-NH3 PET scans were concordant with the final diagnosis (100%, 8/8). The lesions with recurrent tumor showed moderately to markedly increased 13N-NH3 uptake (grade = 4–5). The lesions with radiation necrosis showed absent or less 13N-NH3 uptake than surrounding area (grade = 1–2). The FDG PET scans were concordant with the final diagnosis in six of eight lesions (75%, 6/8), and there were one false-negative result and one false-positive result. The diagnostic result of 13N-NH3 PET was discordant with FDG PET in two lesions. One lesion with gliosis and radiation necrosis showed slightly increased FDG uptake (grade = 4), but less 13N-NH3 uptake (grade = 2). The other lesion with anaplastic astrocytoma showed moderately increased 13N-NH3 uptake (grade = 4), but slightly less FDG uptake than surrounding area (grade = 2). The recurrent astrocytomas showed increased 13N-NH3 uptake, and the radiation necrosis showed absent or less 13N-NH3 uptake, and 13N-NH3 seem superior to 18F-FDG for this purpose, suggesting that 13N-NH3 is a promising tracer for separating radiation necrosis from astrocytoma recurrence. However, the patient population in this study was small. Thus, the further studies are needed to settle this issue.


  • PET Imaging of cerebral astrocytoma with 13N-ammonia

    by Zhang Xiangsong, Liang Changhong, Chen Weian, Zhou Dong

    We performed this study in order to assess the clinical potential of 13N-ammonia PET in patients with cerebral astrocytoma. Dynamic 13N-ammonia PET was performed in 25 patients with suspected cerebral gliomas or recurrent cerebral astrocytomas (19 male and 6 female patients; age range 18–64 years) detected by MRI. The histopathological diagnoses were made for all cases either by biopsy or craniotomy, except for one patient with brain infarction and one patient with brain radiation necrosis confirmed by repeated MRI imaging. PET images were visually inspected, and the tumor-to-white matter count (T/W) ratios and the perfusion index (PI) of the tumors were determined. Six out of nine cases of low-grade gliomas were detected with 13N-ammonia PET, and three non-astrocytoma low-grade gliomas were not detected with 13N-ammonia PET. All 11 high-grade astrocytomas exhibited markedly increased uptake of 13N-ammonia. The five non-neoplastic lesions exhibited low uptake, low T/W ratios and low PI. The significant differences were observed between high-grade and low-grade gliomas with respect to both the T/W ratios and PI (T/W ratios: 5.92±2.27, n=11 vs. 1.66±0.61, n=9, Pn=11 vs. 1.60±0.54, n=9, Pn=6 vs. 0.97±0.11, n=5, Pn=6 vs. 0.99±0.03, n=5, P13N-ammonia in cerebral astrocytomas. 13N-ammonia PET may enable differentiation between low- and high-grade astrocytomas, and has the potential to enable differentiation between low-grade astrocytomas and non-neoplastic lesions.


    • 1 January 2005
      • Vol. 46  (1) , 44-7

    Dynamic 13N-ammonia PET: a new imaging method to diagnose hypopituitarism.

    by Zhang Xiangsong, Yue Dianchao, Tang Anwu

    We have developed a new imaging method to evaluate the blood perfusion and ammonia metabolism of the pituitary gland, and we preliminarily assessed its role in the diagnosis of hypopituitarism. Six female healthy volunteers (age range, 20-46 y) and 6 female patients (age range, 23-42 y) were enrolled in this study. Dynamic (13)N-NH(3) PET was performed. Time-activity curves for the pituitary gland and internal carotid artery were generated by setting regions of interest on the transverse planes of the pituitary gland. The standardized uptake value of the pituitary gland, the radioactive ratio of pituitary to thalamus (P/T), and the first-pass uptake rate of ammonia in the pituitary gland were calculated. (13)N-Ammonia was extracted rapidly by pituitary tissue in the first 120 s after injection and trapped in pituitary tissue in the healthy volunteers. Three to 20 min after injection, the pituitary gland was clearly seen in the healthy volunteers, and the mean (+/-SD) size of the pituitary gland on (13)N-ammonia PET images was (1.09 +/- 0.17 cm) x (1.08 +/- 0.14 cm) x (1.12 +/- 0.09 cm). However, in patients with hypopituitarism, the first-pass uptake rate of ammonia in the pituitary gland was significantly lower than that in healthy volunteers (0.35 +/- 0.10 vs. 0.75 +/- 0.07). On images of patients, the pituitary gland was absent or could not clearly be found, was small or malformed, and showed significantly lower uptake of (13)N-NH(3) than in healthy volunteers (standardized uptake value, 1.15 +/- 0.34 vs. 3.74 +/- 1.44; P/T, 0.65 +/- 0.23 vs. 1.24 +/- 0.34). Dynamic (13)N-ammonia PET can provide information on blood perfusion and metabolism of the pituitary gland and is useful in early monitoring of damage to the pituitary gland and in diagnosing hypopituitarism.